Kesimpta's complicated developmental path has shaped Genmab's approach to partnerships

Much can be learned from Kesimpta's path from disappointing cancer treatment to promising sclerosis medication, according to Genmab's CEO Jan van de Winkel – even if this has led to some frustration along the way.

Photo: Mik Eskestad/ERH

Having already received approvals in the US and Europe, Novartis is currently rolling out the sclerosis drug ofatumumab in what looks like it will be a highly successful year on the market.

Genmab, which originally developed ofatumumab, known today as Kesimpta, now sees the culmination of the potential which the firm saw in the drug, but for a long time, it looked like the potential would not be met. Former owners Glaxosmithkline did not prioritize its sclerosis leg in the ten years it had rights to the drug, even though things started picking up later on.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs